Distinguished in Non-Small Cell Lung Cancer (NSCLC)

Dr. Robert M. Jotte

Hematology | Oncology
1800 Williams St, Ste 200, 
Denver, CO 
Accepting New Patients
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
1800 Williams St, Ste 200, 
Denver, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Jotte is a Hematologist and an Oncologist in Denver, Colorado. Dr. Jotte is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Jotte is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles and participated in 13 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Graduate Institution
Vanderbilt University School Of Medicine
Residency
University of Colorado School of Medicine (CU Anschutz Medical Campus)
Specialties
Hematology
Oncology
Licenses
Internal Medicine in CO
Fellowships
University of Colorado School of Medicine (CU University of Colorado Anschutz Medical Campus)
Hospital Affiliations
Parker Adventist Hospital
Sky Ridge Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Rocky Mountain Cancer Centers LLP
1800 Williams St, Ste 200, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Dostarlimab, Pembrolizumab, Chemotherapy
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Enrollment Status: Terminated
Publish Date: March 13, 2023
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Unknown
Publish Date: March 09, 2023
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 18 Less Clinical Trials

34 Total Publications

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Journal: Nature communications
Published: June 24, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. David R. Camidge
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. David R. Camidge
Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (14.8 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Camidge is an Oncologist in Aurora, Colorado. Dr. Camidge is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Camidge is currently accepting new patients.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Robert C. Doebele
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Robert C. Doebele
Oncology
12605 E 16th Ave, 
Aurora, CO 
 (14.8 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances

Robert Doebele is an Oncologist in Aurora, Colorado. Dr. Doebele is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Eric Bernicker
Hematology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Eric Bernicker
Hematology | Oncology

Catholic Health Initiatives Colorado

14300 Orchard Pkwy, Fl 3, 
Westminster, CO 
 (30.1 miles away)
303-426-2580
Languages Spoken:
English
See accepted insurances

Eric Bernicker is a Hematologist and an Oncologist in Westminster, Colorado. Dr. Bernicker is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma of the Eye, Tissue Biopsy, and Gamma Knife Radiosurgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jotte's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 65 Advanced Conditions
View All 179 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile